Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03200093 · ClinicalTrials.gov registry record · Phase 4
Oral Vancomycin for Preventing Clostridium Difficile Recurrence
A Phase 4 study, sponsored by Rochester General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT03200093: Clinical Trial Phase 4 study, sponsored by Rochester General Hospital.
NCT03200093 is a Phase 4 study that was terminated before completion, run by Rochester General Hospital. The registered enrollment target is 65 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03200093, a Phase 4 study, was terminated before completion, sponsored by Rochester General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study evaluates the role of oral vancomycin in the prevention of recurrent Clostridium difficile for hospitalized patients receiving systemic antibiotic therapy. Half of participants will receive oral vancomycin daily, while the other half will receive a placebo.
Primary Outcome
A positive Clostridium difficile stool test in the 30 days following completion of the systemic antibiotic treatment.
Interventions
- DRUG Placebo
- DRUG Oral Vancomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2017-06-08 |
| Est. Completion | 2021-04-22 |
| Phase | Phase 4 |
Why NCT03200093 stopped before completion
NCT03200093 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03200093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03200093 about?
NCT03200093 is a clinical study titled "Oral Vancomycin for Preventing Clostridium Difficile Recurrence". This study evaluates the role of oral vancomycin in the prevention of recurrent Clostridium difficile for hospitalized patients receiving systemic antibiotic therapy. Half of participants will receive oral vancomycin daily, while the other half will receive a placebo.
What is the current status of trial NCT03200093?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2017-06-08. Estimated completion is 2021-04-22.
What interventions are being tested in trial NCT03200093?
The interventions under investigation include: Placebo (DRUG), Oral Vancomycin (DRUG).
Who is sponsoring clinical trial NCT03200093?
This trial is sponsored by Rochester General Hospital, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03200093's enrollment target sits among peer trials
65 1091st of 2000 higher than 903 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI